Neuroimmunology Drugs Market
Neuroimmunology Drugs Market Forecasts to 2030 - Global Analysis By Product Type (Monoclonal Antibodies, Small Molecules, Recombinant Protein, Cytokines, Lymphocytes and Other Product Types), Indication and By Geography
|
Years Covered |
2021-2030 |
|
Estimated Year Value (2023) |
US $23.87 BN |
|
Projected Year Value (2030) |
US $45.05 BN |
|
CAGR (2023 - 2030) |
9.5% |
|
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
|
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
|
Largest Market |
Asia Pacific |
|
Highest Growing Market |
North America |
According to Stratistics MRC, the Global Neuroimmunology Drugs Market is accounted for $23.87 billion in 2023 and is expected to reach $45.05 billion by 2030 growing at a CAGR of 9.5% during the forecast period. The market for neuroimmunology drugs is mostly focused on the treatment of illnesses involving the neurological and immune systems. This covers conditions that affect the neurological system, such as neuromyelitis optica (NMO), multiple sclerosis (MS), and other autoimmune illnesses. Many of the neurological disorders in this area fall within the category of autoimmune illnesses, in which the immune system misidentifies and attacks nervous system components, including the myelin sheath in multiple sclerosis (MS).
Market Dynamics:
Driver:
Increasing incidence of neuroimmunological disorders
As more people receive diagnoses for neuroimmunological illnesses, there will be a greater number of patients in need of care thus the need for neuroimmunology medications is fueled by this. Increased efforts are being made in research and development to identify more effective therapies as a result of the rising occurrence of these conditions. Pharmaceutical corporations allocate resources towards the creation of novel medications to cater to the growing number of patients. The creation of novel medicines is aided by the requirement to serve a wider patient population and to enhance treatment outcomes; scientists and pharmaceutical companies investigate fresh strategies and cutting-edge medication prospects.
Restraint:
High development costs
Research & development investment may be discouraged by high development costs and it may be financially difficult for startups and smaller pharmaceutical companies to launch or maintain medication development projects for neuroimmunological illnesses. In order to recover development expenses and generate a profit, neuroimmunology pharmaceutical companies could set their prices at premium levels. Thus, the excessive medicine costs may make treatment less effective by limiting patient access and affordability.
Opportunity:
Innovative drug developments
New drug targets, routes, and possible treatments are found as a result of scientific advances. This motivates the creation of novel medications and therapeutic modalities for neuroimmunological illnesses. Research improvements enable collaboration among academic institutions, research groups, and pharmaceutical businesses. Moreover, the knowledge exchange and medication development are accelerated by this group effort and research progresses in identifying certain cellular and molecular targets linked to neuroimmunological diseases. As a result, specific treatments that target the underlying causes of various illnesses and modify the immune response are developed.
Threat:
Intense rivalry
Competition that is too fierce might put pressure on pricing because businesses would drop the price of their drugs to get or keep market share. This may have an effect on the profitability of medication research, even while it can help patients by saving money. Drug research and approval processes may be hurried by pharmaceutical corporations in an effort to stay competitive, raising questions about their efficacy and safety. Patient safety as well as industry confidence may be jeopardized by this. To mitigate the possible adverse consequences of market competition, regulatory supervision, quality benchmarks, and a dedication to therapeutic advancement while upholding rigorous R&D standards are crucial.
Covid-19 Impact
Lockdowns and other limitations caused several research activities including clinical trials and laboratory research to be postponed or hindered. This slowed down the development of on-going neuroimmunology medication initiatives. Some pharmaceutical firms may have changed their focus away from developing drugs for neuroimmunology and instead concentrated their research efforts and resources toward COVID-19-related therapies and vaccines. This resulted in possible shortages and production delays of pharmaceuticals thus negatively impacted the market growth.
The monoclonal antibodies segment is expected to be the largest during the forecast period
The monoclonal antibodies segment is estimated to have a lucrative growth, as these disease modifying treatments for neuroimmunological conditions including multiple sclerosis (MS) and neuromyelitis optica (NMO), monoclonal antibodies are frequently used. With the goal of lowering inflammation and suppressing the inflammatory response, these mAbs may be able to delay the course of the illness and avoid relapses. A major factor in many neuroimmunological illnesses is inflammation and inflammation can be lessened by monoclonal antibodies, which can aid with discomfort relief and stop more nerve tissue damage. Certain mAbs function by preventing the autoimmune system from attacking nervous system elements like the myelin sheath thus they aid in preventing harm to the neurological system by doing this.
The multiple sclerosis segment is expected to have the highest CAGR during the forecast period
The multiple sclerosis segment is anticipated to witness the highest CAGR growth during the forecast period, as it is one of the most common neurological disorders in the market for neuroimmunology medications is multiple sclerosis (MS). The protective myelin layer that envelops nerve fibres in the central nervous system (CNS) is wrongly attacked by the immune system in multiple sclerosis (MS), an autoimmune illness. Numerous neurological symptoms are caused by this illness. Moreover novel treatments are being developed and current medications are being repurposed for the treatment of multiple sclerosis as a result of on-going research thus the goals of these cutting-edge treatments are better results and more treatment alternatives.
Region with largest share:
Asia Pacific is projected to hold the largest market share during the forecast period owing to neuroimmunological diseases like multiple sclerosis, neuromyelitis optica, and other autoimmune nervous system illnesses have become more common in the Asia-Pacific area. Each nation and area has a different precise prevalence as a result of improved treatment options, early diagnosis, and growing awareness of neuroimmunological illnesses. The management of neuroimmunological illnesses is being improved by a number of regional governments. This entails providing money for research, expanding the infrastructure for healthcare, and encouraging early detection and intervention.
Region with highest CAGR:
North America is projected to have the highest CAGR over the forecast period; owing to the clinical trials for medications linked to neuroimmunology which are mostly conducted in North America. It's a desirable place to do clinical research because of its strong healthcare system, research institutes, and varied patient base. The U.S. Food and Drug Administration (FDA) and Health Canada are two regulatory bodies that guarantee the safety and effectiveness of neuroimmunology medications, creating a well-established regulatory framework for drug approval. In North America, a large number of patients have health insurance, which can help to lower out-of-pocket treatment expenses and improve access to neuroimmunology medications.
Key players in the market
Some of the key players profiled in the Neuroimmunology Drugs Market include Biogen, Hoffmann-La Roche Ltd, T3D Therapeutics, Novartis AG, Celgene Corp, Merck KGaA, Johnson & Johnson, Eisai Co Ltd, Sanofi, Actelion Pharmaceuticals Ltd., ImmunoBrain Checkpoint, Lundbeck, Eli Lilly, AstraZeneca, UCB SA, AB Science S.A., AstronauTx, Genetech Inc, Inflammasome Therapeutics and TauRX Therapeutics Ltd
Key Developments:
In September 2023, Biogen Inc has completed the acquisition of Reata Pharmaceuticals, Inc. a company focused on developing therapeutics that regulates cellular metabolism and inflammation in serious neurologic diseases.
In June 2023, Roche announced that they had entered into a definitive agreement to acquire Telavant Holdings, Inc. (Telavant), a Roivant company, owned by Roivant Sciences Ltd. and Pfizer Inc. The agreement includes the development, manufacturing and commercialisation rights in the US and Japan for Telavant’s RVT-3101.
In April 2023, T3D Therapeutics, Inc. a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer’s disease (AD), announced the initiation of dosing in a Phase 2 clinical study of neurometabolic regulator
Product Types Covered:
• Monoclonal Antibodies
• Small Molecules
• Recombinant Protein
• Cytokines
• Lymphocytes
• Other Product Types
Indications Covered:
• Multiple Sclerosis
• Alzheimer’s Disease
• Parkinson's Disease
• Myasthenia Gravis
• Guillain-Barre Syndrome
• Neuromyelitis Optica Spectrum Disorder
• Amyotrophic Lateral Sclerosis
• Chronic Inflammatory Demyelinating Polyradiculoneuropathy
• Other Indications
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Neuroimmunology Drugs Market, By Product Type
5.1 Introduction
5.2 Monoclonal Antibodies
5.3 Small Molecules
5.4 Recombinant Protein
5.5 Cytokines
5.6 Lymphocytes
5.7 Other Product Types
6 Global Neuroimmunology Drugs Market, By Indication
6.1 Introduction
6.2 Multiple Sclerosis
6.3 Alzheimer’s Disease
6.4 Parkinson's Disease
6.5 Myasthenia Gravis
6.6 Guillain-Barre Syndrome
6.7 Neuromyelitis Optica Spectrum Disorder
6.8 Amyotrophic Lateral Sclerosis
6.9 Chronic Inflammatory Demyelinating Polyradiculoneuropathy
6.10 Other Indications
7 Global Neuroimmunology Drugs Market, By Geography
7.1 Introduction
7.2 North America
7.2.1 US
7.2.2 Canada
7.2.3 Mexico
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.3.3 Italy
7.3.4 France
7.3.5 Spain
7.3.6 Rest of Europe
7.4 Asia Pacific
7.4.1 Japan
7.4.2 China
7.4.3 India
7.4.4 Australia
7.4.5 New Zealand
7.4.6 South Korea
7.4.7 Rest of Asia Pacific
7.5 South America
7.5.1 Argentina
7.5.2 Brazil
7.5.3 Chile
7.5.4 Rest of South America
7.6 Middle East & Africa
7.6.1 Saudi Arabia
7.6.2 UAE
7.6.3 Qatar
7.6.4 South Africa
7.6.5 Rest of Middle East & Africa
8 Key Developments
8.1 Agreements, Partnerships, Collaborations and Joint Ventures
8.2 Acquisitions & Mergers
8.3 New Product Launch
8.4 Expansions
8.5 Other Key Strategies
9 Company Profiling
9.1 Biogen
9.2 Hoffmann-La Roche Ltd
9.3 T3D Therapeutics
9.4 Novartis AG
9.5 Celgene Corp
9.6 Merck KGaA
9.7 Johnson & Johnson
9.8 Eisai Co Ltd
9.9 Sanofi
9.10 Actelion Pharmaceuticals Ltd.
9.11 ImmunoBrain Checkpoint
9.12 Lundbeck
9.13 Eli Lilly
9.14 AstraZeneca
9.15 UCB SA
9.16 AB Science S.A.
9.17 AstronauTx
9.18 Genetech Inc
9.19 Inflammasome Therapeutics
9.20 TauRX Therapeutics Ltd
List of Tables
1 Global Neuroimmunology Drugs Market Outlook, By Region (2021-2030) ($MN)
2 Global Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
3 Global Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
4 Global Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
5 Global Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
6 Global Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
7 Global Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
8 Global Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
9 Global Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
10 Global Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
11 Global Neuroimmunology Drugs Market Outlook, By Alzheimer’s Disease (2021-2030) ($MN)
12 Global Neuroimmunology Drugs Market Outlook, By Parkinson's Disease (2021-2030) ($MN)
13 Global Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
14 Global Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
15 Global Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
16 Global Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
17 Global Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
18 Global Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
19 North America Neuroimmunology Drugs Market Outlook, By Country (2021-2030) ($MN)
20 North America Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
21 North America Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
22 North America Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
23 North America Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
24 North America Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
25 North America Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
26 North America Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
27 North America Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
28 North America Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
29 North America Neuroimmunology Drugs Market Outlook, By Alzheimer’s Disease (2021-2030) ($MN)
30 North America Neuroimmunology Drugs Market Outlook, By Parkinson's Disease (2021-2030) ($MN)
31 North America Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
32 North America Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
33 North America Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
34 North America Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
35 North America Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
36 North America Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
37 Europe Neuroimmunology Drugs Market Outlook, By Country (2021-2030) ($MN)
38 Europe Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
39 Europe Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
40 Europe Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
41 Europe Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
42 Europe Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
43 Europe Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
44 Europe Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
45 Europe Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
46 Europe Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
47 Europe Neuroimmunology Drugs Market Outlook, By Alzheimer’s Disease (2021-2030) ($MN)
48 Europe Neuroimmunology Drugs Market Outlook, By Parkinson's Disease (2021-2030) ($MN)
49 Europe Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
50 Europe Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
51 Europe Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
52 Europe Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
53 Europe Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
54 Europe Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
55 Asia Pacific Neuroimmunology Drugs Market Outlook, By Country (2021-2030) ($MN)
56 Asia Pacific Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
57 Asia Pacific Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
58 Asia Pacific Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
59 Asia Pacific Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
60 Asia Pacific Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
61 Asia Pacific Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
62 Asia Pacific Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
63 Asia Pacific Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
64 Asia Pacific Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
65 Asia Pacific Neuroimmunology Drugs Market Outlook, By Alzheimer’s Disease (2021-2030) ($MN)
66 Asia Pacific Neuroimmunology Drugs Market Outlook, By Parkinson's Disease (2021-2030) ($MN)
67 Asia Pacific Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
68 Asia Pacific Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
69 Asia Pacific Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
70 Asia Pacific Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
71 Asia Pacific Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
72 Asia Pacific Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
73 South America Neuroimmunology Drugs Market Outlook, By Country (2021-2030) ($MN)
74 South America Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
75 South America Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
76 South America Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
77 South America Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
78 South America Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
79 South America Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
80 South America Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
81 South America Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
82 South America Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
83 South America Neuroimmunology Drugs Market Outlook, By Alzheimer’s Disease (2021-2030) ($MN)
84 South America Neuroimmunology Drugs Market Outlook, By Parkinson's Disease (2021-2030) ($MN)
85 South America Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
86 South America Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
87 South America Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
88 South America Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
89 South America Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
90 South America Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
91 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Country (2021-2030) ($MN)
92 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
93 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
94 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
95 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
96 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
97 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
98 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
99 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
100 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
101 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Alzheimer’s Disease (2021-2030) ($MN)
102 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Parkinson's Disease (2021-2030) ($MN)
103 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
104 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
105 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
106 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
107 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
108 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
